HDAC8 and nonpapillary renal cell carcinoma: Thus, we applied PROTAC technology to optimize HDAC8 inhibitors (PCI‐34051), which not only inhibited the activity of HDAC8 but also reduced the expression of HDAC8 in ccRCC cells.